Statement re Change of Corporate Adviser

DXS International

05/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240905:nGNErJs73&default-theme=true


DXS INTERNATIONAL PLC

(AQSE: DXSP)

Change of Adviser

DXS International plc (AQSE: DXSP) ("DXS" or the "Company"), the digital
clinical decision support company, is pleased to announce that it has
appointed Hybridan LLP as its AQSE Corporate Adviser with immediate effect.
Hybridan remains AQSE Corporate Broker to the Company.

The Directors of DXS accept responsibility for the contents of this
announcement.

This announcement contains information which, prior to its disclosure, was
inside information as stipulated under Regulation 11 of the Market Abuse
(Amendment) (EU Exit) Regulations 2019/310 (as amended).The Directors of DXS
International plc accept responsibility for this announcement

Contacts:

David Immelman 
Chief Executive
DXS International plc        
david@dxs-systems.com
https://www.dxs-systems.co.uk        
Tel: 01252 719800

Claire Louise Noyce
AQSE Stock Exchange Corporate Adviser & Corporate Broker
Hybridan LLP        
claire.noyce@hybridan.com
www.hybridan.com        
Tel: +44 20 3764 2341

About DXS:

DXS International presents up to date treatment guidelines and
recommendations, from Clinical Commissioning Groups and other trusted NHS
sources, to doctors, nurses and pharmacists in their workflow and during the
patient consultation. This effective clinical decision support ultimately
translates to improved healthcare outcomes delivered more cost effectively and
which should significantly contribute towards the NHS achieving its projected
efficiency savings